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Abstract
The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator’s meeting was
held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical
experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease
dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the
LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living
with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals,
and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new
therapeutics.
Keywords: Lewy body dementia, Lewy Body Dementia Association, Parkinson’s disease dementia
Introduction
The first Lewy Body Dementia Association (LBDA) Re-
search Centers of Excellence (RCOE) Investigator’s
meeting was held on December 14, 2017, in New Or-
leans. The program was established to increase patient
access to clinical experts on Lewy body dementia (LBD),
which includes dementia with Lewy bodies (DLB) and
Parkinson’s disease dementia (PDD), and to create a
clinical trials-ready network. Mayo Clinic, Rochester
MN, was designated the coordinating center following a
competitive application process. The 24 centers were se-
lected by an application and peer-review process.
Background
The top national research priority for LBD is to initiate
clinical trials to address symptoms that have the greatest
impact on patient function and caregiver burden. LBDA’s
RCOE program establishes infrastructure to run
multi-center studies with expertise, centralization, and
standardized data collection. The program will yield a
well-characterized, nationwide group of LBD patients for
rapid recruitment into therapeutic trials.
Aims of the program
The major aims are to:
 Increase access to high-quality clinical care
 Increase access to support for people living with
LBD and their caregivers
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 Increase knowledge of LBD among medical and allied
(or other) professionals
 Create infrastructure for a clinical trials-ready network
as well as resources to advance the study of new
therapeutics.
Four working groups (WG) were created to pursue the
LBDA RCOE aims. WG chairs (JEG, JGG, HP, MJA, DK,
DI, JBL, AS) were selected; all PIs self-selected in which
WGs they would participate. Each WG had several goals
to achieve for the meeting, summarized below.
Working groups
Clinical care and professional education WG
WG goals are to ascertain best practice clinical guide-
lines and identify opportunities for professional LBD
education. The group discussed strategies to solicit feed-
back from experts and other stakeholders on diagnosis
and symptom management. Diagnosis using the fourth
consensus report of the DLB consortium was empha-
sized [1], but challenges regarding its widespread imple-
mentation remain. Important clinical milestones in LBD
management include referrals to allied health therapies,
utilization of community resources, and entry into
skilled nursing and long-term care facilities. Examples of
LBD research and clinical service toolkit development
such as the DIAMOND-Lewy research program may
help inform the LBDA RCOE efforts [2].
Increasing awareness and disseminating knowledge on
LBD to healthcare professionals remains a critical prior-
ity. Key target audiences include (a) healthcare profes-
sionals such as physicians, advanced practice providers,
and trainees practicing in Neurology, Psychiatry, Geriat-
ric Psychiatry, Geriatrics, Sleep Medicine, Cardiology,
Urology, Gastroenterology, and Palliative Care; those
practicing in Psychology and Neuropsychology; and
those practicing in long-term care settings; (b) allied
health professionals (nurses, social work, physical, occu-
pational and speech therapy, nutrition, arts/music ther-
apy, chaplaincy, and hospice); and (c) healthcare workers
in specific environments, including hospitals, assisted
living facilities, long-term care facilities, and adult day
programs.
Community education and support WG
WG goals are to develop core themes and materials, and
identify opportunities for community education, assist-
ance for support groups, and best practices for caregiver
education and support for non-pharmacological ap-
proaches to behavioral changes in LBD.
The WG surveyed 23 RCOE sites. Ten sites (43%)
already hosted LBD-specific support groups, most com-
monly targeting caregivers alone or caregivers and
people with LBD together. These groups were typically
led by either clinical staff or former caregivers and met
on a monthly basis. Sites preferred either in-person or
mixed in-person/virtual monthly support groups led by
clinical staff. Most sites favored targeting caregivers and/
or early-stage people with LBD; some sites suggested
support groups for moderate- and late-stage people with
LBD. Trained facilitators were described as essential.
LBDA RCOE sites commonly educate people with
LBD and their families with LBDA-produced materials,
the LBD booklet from the National Institutes of Health,
and materials produced by the individual sites.
Clinical trial design and optimization WG
WG goals are to identify ongoing or planned therapeutic
trials in LBD, identify and address key gaps in clinical as-
sessment tools for use in diagnosis of LBD and clinical
trials, identify current or emerging biomarkers relevant
for LBD clinical trials, and develop strategies for imple-
mentation. Collectively, the LBDA RCOE network is es-
timated to see > 2600 new patient visits (~ 1300 DLB
and ~ 1300 PDD) and > 7,500 return visits (~ 3000 DLB
and ~ 4500 PDD) annually. The majority of sites are very
active in clinical trials for LBD and related disorders,
with 16 centers participating in ≥ 1 clinical trial for LBD
and collectively enrolling ~ 430 LBD patients in the past
year. Furthermore, 21 sites participated in ≥ 2 and 18
sites are active in ≥ 5 clinical trials for related neurode-
generative disorders.
The RCOE investigator survey and discussion revealed
a strong interest in trials focused on both symptomatic
therapies and potential disease-modifying agents. Priori-
tized targets for non-pharmacological interventions in-
cluded caregiver-stress, agitation, and motor function
limitations. One critical need is to identify and develop
clinically meaningful DLB clinical outcome measures, in-
cluding ways to account for and/or quantify the effects
of cognitive fluctuations. Emerging biomarkers were
classified on their potential for diagnostic and/or prog-
nostic use based on review of the current state of the
science. High-yield applications of diagnostic biomarkers
for LBD included identifying prodromal disease, differenti-
ation of LBD from other dementias, and stratification of
biologically meaningful subgroups of DLB patients such
as those with significant AD co-pathology or those har-
boring a glucocerebrosidase gene mutation. There was
strong interest in the need for alpha-synuclein-specific
markers; however, it was felt that current assays require
further development and validation. Other top priorities
identified included tissue-validation and standardization
of imaging and fluid biomarkers, and the development of
an infrastructure for sharing biomarker specimens and
data that will be obtained in future clinical trials to the re-
search community at large.
Peterson et al. Alzheimer's Research & Therapy           (2019) 11:23 Page 2 of 4
Industry engagement WG
WG goals are to determine general principles for interact-
ing with industry partners and determine requirements
for industry-sponsored clinical trials, including data and
sample sharing and publication plan, contract and budget
development, and protocol optimization. The WG serves
as a central resource for exploring collaborations between
the RCOE and industry on LBD clinical trials.
To maximize efficiencies in collaborations with indus-
try, this working group has proposed an accessible, cen-
tralized data resource on the clinical trial capabilities of
all RCOE sites. This will facilitate exploring clinical re-
search collaborations and expedite site selection for
industry-sponsored trials. Each site will determine its
unique clinical trial capacity, its ability to recruit people
with LBD for trial enrollment, and its testing capabilities.
The RCOE program will strive to use a standardized
contract and a central institutional review board. In par-
allel with the effort to build the infrastructure, this work-
ing group will provide guidance on establishing expert
panels to advise clinical trial sponsors.
Conclusions
The LBDA established the RCOE program to accelerate
access to high-quality care and support, increase disease
awareness among healthcare providers, and advance the
study of symptomatic and disease-modifying treatments.
As the RCOE program grows and evolves, it will con-
tinue to share its successes and lessons learned with the
scientific community. The next RCOE Principal Investi-
gator’s meeting will be in June 2019.
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